CANbridge Pharma Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Public

  • Employees
  • 100

Employees

  • Stock Symbol
  • 01228

Stock Symbol

  • Share Price
  • $0.04
  • (As of Friday Closing)

CANbridge Pharma General Information

Description

Canbridge Pharmaceuticals Inc is a biopharmaceutical company. It is committed to the research, development, and commercialization of biotech therapies targeting rare diseases and rare oncology. The company's core product in the rare oncology area CAN008, is a glycosylated CD95-Fc fusion protein being developed for the treatment of glioblastoma multiforme (GBM). In the rare disease area, the company have seven biologics and small molecules products and product candidates for the treatment of Hunter Syndrome (MPS II) and other lysosomal storage disorders (LSDs), complement mediated disorders, hemophilia A, metabolic disorders, and rare cholestatic liver diseases including ALGS, PFIC and BA. Its pipeline consists of biologics, small molecules, and gene therapy solutions and 13 drugs.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Stock Exchange
HKG
Corporate Office
  • Unit 18, 6th Floor, Building 21
  • No.388 Xinping Street Suzhou Industrial Park
  • Suzhou
  • China
+86 010 0000 0000

CANbridge Pharma Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CANbridge Pharma Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.04 $0.04 $0.03 - $0.24 $17.7M 425M 82.4K -$0.13

CANbridge Pharma Financials Summary

In Thousands,
USD
TTM 31-Dec-2023 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 37,347 37,347 66,472 821,444
Revenue 14,540 14,540 11,726 4,826
EBITDA (49,811) (49,811) (68,086) (164,289)
Net Income (53,547) (53,547) (71,790) (166,795)
Total Assets 55,774 55,774 101,756 140,023
Total Debt 20,022 20,022 22,507 8,174
Public Fundamental Data provided by Morningstar, Inc. disclaimer

CANbridge Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore CANbridge Pharma‘s full profile, request access.

Request a free trial

CANbridge Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Canbridge Pharmaceuticals Inc is a biopharmaceutical company. It is committed to the research, development, and commerci
Pharmaceuticals
Suzhou, China
100 As of 2023
00000
00000 0000-00-00
00000000 00000

000000

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu
0000 000000000
La Jolla, CA
000 As of 0000
00000
00.00 0000-00-00
000000&0 00000

000000

rehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excep
0000 000000000
Grand Cayman, Cayman Islands
00000 As of 0000
00.000
00000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CANbridge Pharma Competitors (63)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Inhibrx Formerly VC-backed La Jolla, CA 000 00000 000000&0 00000
BeiGene Formerly PE-Backed Grand Cayman, Cayman Islands 00000 00.000 00000000000 00.000
Dicerna Pharmaceuticals Formerly VC-backed Lexington, MA 000 00000 000000&0 00000
Regulus Therapeutics Formerly VC-backed San Diego, CA 00 00000 000000000 00000
Innovent Biologics Formerly PE-Backed Suzhou, China 0000 00.000 000000000 00.000
You’re viewing 5 of 63 competitors. Get the full list »

CANbridge Pharma Patents

CANbridge Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022332298-A1 Aav particles comprising a liver-tropic capsid protein and alpha-galactosidase and their use to treat fabry disease Pending 25-Aug-2021 000000000
AU-2022335593-A1 Aav particles comprising liver-tropic capsid protein and acid alpha-glucosidase and use to treat pompe disease Pending 25-Aug-2021 000000000
CA-3230004-A1 Aav particles comprising liver-tropic capsid protein and acid alpha-glucosidase and use to treat pompe disease Pending 25-Aug-2021 000000000
CA-3229998-A1 Aav particles comprising a liver-tropic capsid protein and alpha-galactosidase and their use to treat fabry disease Pending 25-Aug-2021 000000000
EP-3644062-A1 Method for predicting response of esophagus cancer to anti-erbb3 antibody therapy, and kit Active 22-Jun-2017 C07K16/32
To view CANbridge Pharma’s complete patent history, request access »

CANbridge Pharma Executive Team (12)

Name Title Board Seat Contact Info
James Xue Ph.D Founder, Chief Executive Officer and Chairman
Glenn Hassan Chief Financial Officer
Gerald Cox MD Chief Development Strategist and Interim Chief Medical Officer
James Geraghty JD Independent Non-Executive Director
You’re viewing 4 of 12 executive team members. Get the full list »

CANbridge Pharma Board Members (3)

Name Representing Role Since
James Xue Ph.D CANbridge Pharma Founder, Chief Executive Officer and Chairman 000 0000
Mark Bamforth CANbridge Pharma Strategic Board Advisory 000 0000
You’re viewing 2 of 3 board members. Get the full list »

CANbridge Pharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CANbridge Pharma Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore CANbridge Pharma‘s full profile, request access.

Request a free trial

CANbridge Pharma FAQs

  • When was CANbridge Pharma founded?

    CANbridge Pharma was founded in 2012.

  • Who is the founder of CANbridge Pharma?

    James Xue Ph.D is the founder of CANbridge Pharma.

  • Who is the CEO of CANbridge Pharma?

    James Xue Ph.D is the CEO of CANbridge Pharma.

  • Where is CANbridge Pharma headquartered?

    CANbridge Pharma is headquartered in Suzhou, China.

  • What is the size of CANbridge Pharma?

    CANbridge Pharma has 100 total employees.

  • What industry is CANbridge Pharma in?

    CANbridge Pharma’s primary industry is Pharmaceuticals.

  • Is CANbridge Pharma a private or public company?

    CANbridge Pharma is a Public company.

  • What is CANbridge Pharma’s stock symbol?

    The ticker symbol for CANbridge Pharma is 01228.

  • What is the current stock price of CANbridge Pharma?

    As of 14-Jun-2024 the stock price of CANbridge Pharma is $0.04.

  • What is the current market cap of CANbridge Pharma?

    The current market capitalization of CANbridge Pharma is $17.7M.

  • What is CANbridge Pharma’s current revenue?

    The trailing twelve month revenue for CANbridge Pharma is $14.5M.

  • Who are CANbridge Pharma’s competitors?

    Inhibrx, BeiGene, Dicerna Pharmaceuticals, Regulus Therapeutics, and Innovent Biologics are some of the 63 competitors of CANbridge Pharma.

  • What is CANbridge Pharma’s annual earnings per share (EPS)?

    CANbridge Pharma’s EPS for 12 months was -$0.13.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »